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Since the initial work of Cori and Cori (1-5) on the effects of 
epinephrine on glucose homeostasis, many investigations have been 
undertaken to clarify the role of adrenergic factors in the economy 
of carbohydrate metabolism. In particular, epinephrine has been shown 
to stimulate liver and muscle glygogenolysis in vivo (4, 6, 7, 8) and in 
vitro (9, 10) resulting in increases in glucose and lactic acid concentra¬ 
tions in the blood. Also, epinephrine has been shown to stimulate lipolysis 
with the consequent release of free fatty acids and glycerol into the blood¬ 
stream (11, 12). In addition, infusions of epinephrine in diabetic children 
have been shown to greatly increase the level of ketones in the blood (13). 
More recently, the role of epinephrine vis-a-vis insulin secretion has been 
investigated with the demonstration that epinephrine inhibits insulin 
output (14). 
Although the above mechanisms of epinephrine's action have been elucidated, 
little is known regarding the effect of catecholamines on amino acid metabolism 
and gluconeogenesis. Specifically, the effect of adrenergic factors, parti¬ 
cularly, epinephrine, upon individual arterial amino acid levels and splanchnic 
uptake of amino acids has not been elucidated. Previous evidence suggests 
a decrease in the total amino acid content of the blood after epinephrine 
(15, 16, 17) but this does not take into account either the individual amino 
acid levels cr the balance across the liver. With regard to the role of 
epinephrine in the splanchnic utilization of amino acids evidence is available 
only in terms of nonmetabolizable amino acids. Specifically, Chambers et. al. 
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found an increased uptake of the nonmetabolizable amino acid, a-amino- 
isobutyric acid (AIB), in the perfused rat liver after in vivo pretreat¬ 
ment with epinephrine (18). Sanders and Riggs reported an increased uptake 
of two nonmetabolizable labelled amino acids following insulin-induced hypo¬ 
glycemia suggesting an effect of endogenous epinephrine in restoring glucose 
balance (19). However, in neither study were endogenous amino acid levels 
measured in arterial blood nor was splanchnic amino acid balance investigated. 
This lack of information assumes importance in view of the recent demonstra¬ 
tion of the prominent role of endogenous amino acids, in particular alanine, 
in the regulation of gluconeogenesis (20-25). 
With the delineation of the concept of a and 3 receptors at the tissue level 
by Alhquist in 1948 (26) much investigation has also gone into a description 
of the specific receptors at different tissue sites and of the effects of 
blocking agents in modifying the effects of adrenergic agents on splanchnic 
and peripheral glucose metabolism. In recent years the work of Porte and his 
colleagues has demonstrated the important role of the adrenergic nervous 
system in glucose and insulin homeostasis (12, 14, 27, 28). In particular, 
several recent reports indicate the propensity of propranolol, a $-adrenergic 
blocking agent, to cause hypoglycemia in the dog and man. Measuring venous 
glucose levels in anesthetized dogs, Berk and his co-workers described profound 
hypoglycemia after intravenous propranolol over a dose range of 25-600 yg/kg 
(29). Reports in man over the past few years confirm this hypoglycemic poten¬ 
tial of propranolol and have demonstrated its ability to blunt glucose recovery 
after insulin-induced hypoglycemia. In 1966, Kotler and his group reported 
that propranolol precipitated severe attacks of hypoglycemia in a patient who 
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had previously undergone a partial gastrectomy and in an insulin-dependent, 
juvenile onset diabetic (30). In the same year, Abramson et. al. observed 
that propranolol dampened the glucose and free fatty acid rebound to insulin- 
induced hypoglycemia (31). In 1967, Mackintosh reported the case of a nine 
year old girl who suffered hypoglycemic episodes after intravenous propranolol 
during an ear operation and after a 24 hour fast (32). Again in 1967, Bewsher 
observed that oral propranolol lowered blood glucose in exercising subjects 
(33). However, in contrast to the above mentioned reports, Allison and his 
group in 1969 found that therapeutic oral doses of propranolol did not pro¬ 
duce significant hypoglycemia in normal subjects even after a 24 hour fast 
or after walking up an inclined plane (34). 
Despite these reports, the mechanism by which propranolol precipitates or 
potentiates hypoglycemia has not been clarified. The various hypotheses 
proposed have included blockade of hepatic glycogenolysis (29, 30); inhibition 
of muscle glycogenolysis and peripheral lipolysis with a concommitent decrease 
in substrate availability for gluconeogenesis (30, 31, 35, 36); an increase 
in peripheral glucose utilization (36); and possibly direct stimulation of 
insulin secretion (37). Lacking in all these reports has been a definite 
correlation between the observed hypoglycemia of propranolol and its effects 
upon simultaneously determined hepatic glucose production and peripheral glucose 
utilization. 
The present study was designed to further delineate the effects of the 
adrenergic nervous system on glucose homeostasis. Using the hepatic venous 
catheter technique in anesthetized dogs two specific areas of investigation 
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have been pursued: 
(1) A delineation of the effects of epinephrine infusion 
on arterial concentrations and splanchnic exchange of in¬ 
dividual amino acids; and 
(2) An examination of the relative effects of propranolol 
on splanchnic glucose production and peripheral glucose 
consumption. 
In the presentation of the results and in the discussion below, these two 






Twenty-one adult mongrel dogs ranging in weight from 18 to 26 kg. were 
maintained on an ad. lib. standard laboratory diet with free access to water. 
On the day of experimentation after a 12 to 18 hour fast the dogs were 
anesthetized with sodium pentobarbital (30 mg/kg) and placed on a Harvard 
respirator. In the propranolol study the animal's heart rates were continu¬ 
ously monitored by electrocardiography (limb leads). 
CATHETERIZATION, SPLANCHNIC BLOOD FLOW, AND INFUSIONS 
Polyethylene catheters were inserted into an exposed femoral artery, femoral 
vein, and external jugular vein, with an additional catheter placed distally 
in a femoral vein draining the hind limb in the propranolol study. A single 
lumen end-hole cardiac catheter was placed via the opposite external jugular 
vein under fluoroscopic control into the left hepatic vein (38-40). The 
catheter was placed mid-position between the entrance to the hepatic vein and 
the wedge position. The position of the hepatic venous catheter was checked 
continuously by fluoroscopy during the experiment. The catheters were kept 
patent by intermittent flushing with saline. No anticoagulants were used with 
the exception of four of the dogs in the epinephrine study who received 
heparin (5 mg/kg). 
Splanchnic blood flow was estimated by the continuous infusion technique 
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of Bradley and Ingelfinger (41) employing indocyanine green dye* (42). 
After the catheters were in place a priming dose of indocyanine green dye 
was given (0.3 to 0.5 mg/kg) followed by a constant infusion of the dye 
by a Harvard infusion pump via an external jugular venous catheter at rates 
of 0.081 to 0.134 mg/min (43). After a 15 minute equilibration period, 
simultaneous arterial and hepatic venous samples were obtained for blood 
flow analysis. In the epinephrine study samples were collected for blood 
flow determination every 10 minutes during a 30 minute control period, and 
at 10-20 minute intervals for 100 minutes following initiation of the infusion. 
In the propranolol study samples were collected every 15 minutes during the 30 
minute control period and for 180 minutes after initiation of the infusion. 
Following a 30 minute control period, epinephrine! was infused in seven 
dogs over 60 minutes by means of a Harvard infusion pump via a femoral 
vein in a dose of 0.1 yg/kg/min. The epinephrine was diluted in a total 
volume of 50 ml. of isotonic saline to which was added 250 mg. of ascorbic 
acid as an antioxidant. Blood samples for chemical analysis were obtained 
simultaneously from the femoral artery and hepatic vein at 10 minute intervals 
during the control period, and at 10-20 minute intervals during the infusion 
and for 40 minutes following completion of the infusion. 
Propranolol was administered to nine dogs following a 30 minute control 
period. The propranolol^ was given in a dose of 150 yg/kg dissolved in 
* Supplied as Cardiogreen by Hynson, Westcott, and Dunning, 
t Adrenalin Chloride, Parke-Davis. 
4> Inderal, Ayerst. 
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8 to 12 ml. of isotonic saline and injected intravenously over 3 minutes. 
Blood samples for chemical analysis were obtained from the arterial, hepatic 
venous, and deep femoral venous catheters at 30 minute intervals during the 
30 minute control period and for 180 minutes following completion of the 
infusion. In an additional five dogs a 3 minute infusion of 8 to 12 ml. of 
isotonic saline was administered followed by blood sampling at the same 
intervals as in the group receiving propranolol. 
COLLECTION, BLOOD ANALYSIS, AND STATISTICAL ANALYSIS 
Blood samples were collected and placed in heparinized tubes at 4° C until 
the end of the study. At this time the heparinized samples were centrifuged 
at 4° C. Aliquots of the separated plasma were analyzed for indocyanine 
green dye or frozen at -19° C for future analysis of glucose, insulin, and 
amino acids as indicated. Blood glucose was determined in duplicate by the 
glucose oxidase method (44). Individual amino acids were determined in the 
epinephrine study by the automated ion-exchange chromatography technique (45) 
on heparinized plasma deproteinized with sulfosalicyclic acid (46). Plasma 
insulin was measured in the propranolol study by immunoassay using talc to 
separate bound and free insulin (47). The paired t-test was employed in both 





1. Basal Glucose Metabolism 
During the control period, as seen in Figure 1 and Table I, the 
hepatic venous glucose levels consistently exceeded those of arterial 
blood indicating a net splanchnic release of glucose. Splanchnic 
glucose production, calculated from the estimated hepatic blood flow 
and the hepatic venous-femoral arterial glucose difference, and taken 
as a mean of the three sampling periods, was 2.6 mg/kg/minute, a find¬ 
ing in good agreement with previous data in dogs (49) as well as in 
human subjects (50, 51). The basal arterial levels of the individual 
amino acids are shown in Table la. In Figure 2 and Table II, are 
shown those amino acids for which a consistent exchange across the 
splanchnic bed was demonstrable. Noteworthy is the fact that the 
arterial level of alanine exceeded that of all the other amino acids 
with the exception of glutamine. In addition, the splanchnic uptake 
of alanine exceeded that of the other three major gluconeogenic 
amino acids by approximately four-fold. Both these findings are 
consistent with the observations of Felig et. al. in normal postabsorp- 
tive subjects (23, 24) and stress the important role of alanine in basal 
glucose homeostasis. 
2. Response to Epinephrine Infusion 
The infusion of epinephrine resulted in significant changes in the 
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BLOOD GLUCOSE AND SPLANCHNIC GLUCOSE 
PRODUCTION IN THE BASAL STATE 













FIGURE 1 Hepatic venous and femoral arterial blood glucose, and 
splanchnic glucose production in seven anesthetized dogs in the 
basal postabsorptive state. Mean values are shown. Lines at top 




BLOOD GLUCOSE, SPLANCHNIC GLUCOSE PRODUCTION, AND ESTIMATED 











-20 142.5 ± 10.71 125.4 ± 5.7 2.1 + 1.4 352 ± 
-10 147.8 ± 14.0 123.9 ± 6.5 2.9 ± 1.0 404 ± 
0 141.9 ± 10.1 124.4 ± 5.8 2.7 + 1.5 407 ± 
* Splanchnic glucose production. Calculated from the hepatic venous- 
femoral arterial glucose difference and the estimated hepatic blood 
flow. 
t Estimated hepatic blood flow. 
'I Mean ± S.E. 
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TABLE la 
ARTERIAL CONCENTRATION OF 15 INDIVIDUAL AMINO ACIDS 
IN NORMAL POSTABSORPTIVE ANESTHETIZED DOGS 
(N=4) 
Amino Acid Basal 
Alanine 365 ± 
Glycine 137 ± 






Threonine 113 ± 
Leucine 97 ± 
Serine 85 ± 
Isoleucine 53 ± 
Tyrosine 23 ± 





Citrulline 54 ± 
Methionine 32 ± 
Glutamine 527 ± 
Glutamate 57 ± 
Epinephrine* 
72i 353 + 51 
15 130 + 17 
14 145 + 13 
8 74 + 10 
14 105 + 16 
11 101 + 10 
8 75 + 8 
4 59 + 2 
4 21 + 2 
8 62 + 18 
5 48 + 3 
10 51 + 7 
3 31 + 3 
36 450 + 42 
6 53 + 6 
* Samples were obtained 10-20 minutes after the start of the epinephrine 
infusion (0.1 yg/kg/min). 
Mean ± S.E., yMoles/L. 
si 3J3AT 
li iA mi; IMA .IAUUIVICIWI 21 30 W0ITA3TW30W00 JAIMMTHA 
.' >v\ 1 l.\‘TT:iUT23[<[A 3VII<aH0SSAT803 3AM30M HI 
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SPLANCHNIC AMINO ACID UPTAKE OF 
GLUCONEOGENIC AMINO ACIDS IN THE BASAL STATE 
(MEAN ± S.E.,N=4) 
FIGURE 2 Splanchnic uptake of four gluconeogenic amino acids - alanine, 
glycine, threonine, and serine - in four anesthetized dogs in the basal 
postabsorptive state. Mean values are shown. Lines at top of bars 




SPLANCHNIC AMINO ACID UPTAKE OF FOUR GLUCONEOGENIC 
AMINO ACIDS IN THE BASAL STATE 
(N-4) 
Alanine 
72.6 ± 5.0* 
Glycine 
19.1 ± 2.0 
Threonine 
11.1 ± 1.3 
Serine 
15.1 ± 2.2 
* Mean ± S.E., yMoles/min. 
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arterial glucose concentration, in splanchnic glucose production, and in 
the uptake of alanine across the splanchnic bed. As shown in Figure 3 
and Table III, the arterial glucose concentration rose significantly 
from a control value of 125 mg/100 ml to 144 and 142 mg/100 ml 10 to 20 
minutes after beginning the infusion. At the same time splanchnic 
glucose production also increased approximately six-fold from a control 
value of 2.6 to 15.7 mg/kg/min at 20 minutes (pO.05) . In accord with the 
rise in glucose output the splanchnic uptake of three of the four gluconeo¬ 
genic amino acids increased (Figure 4, Table IV). This was mainly a function 
of an increased splanchnic blood flow noted in the four dogs studied. The 
splanchnic uptake of alanine increased 37 per cent from a control value of 
73 yMole/min to 100 yMole/min (p< 0.025). A slight increase in the splanchnic 
uptake of serine (p<0.05) and glycine (0.1>p>0.05) was also observed. 
Despite the increased splanchnic glucose production and increased hepatic 
uptake of alanine, arterial alanine levels did not change significantly 
as seen in Table la. Also noteworthy, was the lack of effect of epinephrine 
infusion on the arterial levels of the other individual amino acids (Table la), 
particularly the insulin sensitive branched-chain amino acids, phenylalanine, 
and tyrosine (Figure 5, Table V) (21, 52, 53). Finally, although not reaching 
significant levels at any one period, splanchnic blood flow tended to increase 
10-20 minutes after initiation of the epinephrine infusion and remained elevated 
throughout the infusion and recovery periods suggesting that epinephrine 
probably augmented splanchnic blood flow. (Table III). 
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ARTERIAL BLOOD GLUCOSE AND SPLANCHNIC 
GLUCOSE PRODUCTION DURING EPINEPHRINE 
INFUSION 
(MEAN ± S.E., N = 7) 
FIGURE 3 Arterial glucose levels and splanchnic glucose production 
in seven anesthetized dogs in the basal postabsorptive state and 
during and after infusion of epinephrine at 0.1 yg/kg/min. Mean 
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SPLANCHNIC UPTAKE OF GLUCONEOGENIC 
AMINO ACIDS BEFORE AND AFTER 
EPINEPHRINE INFUSION 
(MEAN ± S.E., N = 4) 
FIGURE 4 Splanchnic uptake of four gluconeogenic amino acids - alanine, 
glycine, threonine, and serine - in four anesthetized dogs in the 
basal postabsorptive state (cross-hatched bars), and 10-20 minutes 
after initiation of an epinephrine infusion at 0.1 yg/kg/min (stippled 
bars). Mean values are shown. Lines at top of bars represent the 
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ARTERIAL LEVEL OF BRANCHED-CHAIN AMINO ACIDS, 
PHENYLALANINE, AND TYROSINE IN THE BASAL STATE 
AND AFTER EPINEPHRINE INFUSION 
(MEAN ± S.E., Ns4) 
FIGURE 5 Arterial levels of tire branched-chain amino acids, phenylalanine, 
and tyrosine in four anesthetized dogs in the basal postabsorptive 
state (cross-hatched bars), and 10-20 minutes after infusion of epinephrine 
at 0.1 yg/kg/min (stippled bars). Mean values are shown. Lines at 





ARTERIAL LEVEL OF THE BRANCHED-CHAIN AMINO ACIDS, PHENYLALANINE 
AND TYROSINE IN THE BASAL STATE AND AFTER EPINEPHRINE INFUSION 
(N=4) 
Control Epinephrine* Pi- 
Valine 145 + 141' 145 ± 13 N.S. 
Leucine 97 ± 11 
Isoleucine 53 ± 4 
Phenylalanine 48 ± 5 
Tyrosine 23 ± 4 
101 ± 10 
59 + 2 
48 ± 3 





* Samples were obtained 10-20 minutes after the start of the epinephrine 
infusion (0.1 pg/kg/min). 
T P, probability that changes in arterial concentration after epinephrine 
are a chance occurrence (paired t test). 
1 Mean ± S.E., yMoles/L. 
n.IELA" 
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II. PROPRANOLOL 
1. Basal Glucose Production 
As observed in the epinephrine experiment, net splanchnic release of 
glucose was noted during the control period. As anticipated, femoral venous 
glucose levels were below arterial concentrations, indicating peripheral 
glucose consumption in the basal state. The mean arterio-femoral venous 
glucose difference during this period was 5.7 mg/100 ml. Insulin levels 
in the basal state were 10 to 12 yU/ml (Figure 6, Table VI). 
2. Response to Propranolol Infusion 
The infusion of propranolol resulted in significant changes in the arterial 
glucose concentration, in arterial insulin levels, and in the arterio- 
femoral venous glucose difference. On the other hand, splanchnic glucose 
production showed no significant change. As shown in Figure 7 and Table VII, 
the arterial glucose concentration fell significantly by 10 to 15 mg/100 ml 
at 150 minutes. The arterial insulin concentration fell from a mean value 
of 11.3 yU/ml to 5.6 yU/ml at 180 minutes. Despite this fall in insulin 
concentrations, the arterio-femoral venous glucose difference increased three 
to four-fold from a basal value of 5.7 mg/100 ml to 21.6 mg/100 ml. These 
changes were highly significant. In marked contrast to the increase in the 
arterio-femoral venous glucose difference splanchnic glucose production did not 
change significantly from a mean control value of 3 mg/kg/min throughout the 
180 minutes of observation. Particularly noteworthy is the fact that the 
heart rate remained above 100 beats per minute throughout the period of 
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BLOOD GLUCOSE, PERIPHERAL AND 
SPLANCHNIC GLUCOSE BALANCE AND 
ARTERIAL INSULIN LEVELS IN THE BASAL STATE 


























FIGURE 6 Hepatic venous., femoral arterial, and femoral venous blood 
glucose; arterio-femoral venous glucose difference; splanchnic 
glucose production; and arterial insulin levels in nine anesthetized 
dogs in the basal postabsorptive state. Mean values are shown. Lines 
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ARTERIAL BLOOD GLUCOSE, ARTERIAL INSULIN LEVELS 
AND PERIPHERAL AND SPLANCHNIC GLUCOSE BALANCE 
DURING PROPRANOLOL INFUSION (150/ig / kg in 3 min) 
( MEAN ± S.E., N =9) 
-30 0 30 60 90 120 150 180 
TIME (min) 
FIGURE 7 Femoral arterial glucose levels; arterial insulin levels 
arterio-femoral venous glucose difference; and splanchnic glucose 
production in nine anesthetized dogs in the basal postabsorptive 
state and after a 3 minute infusion of propranolol at 150 pg/kg. 
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3. Response to Saline Infusion 
To determine if the anesthesia or catheterization procedures were of them¬ 
selves responsible for the observed changes, five additional dogs were given a 
saline infusion and similarly studied over a four hour period. In marked 
contrast to the propranolol group, as shown in Figure 8 and Table VIII, the 
arterio-femoral venous glucose difference did not rise significantly from 
a mean control value of 8.2 mg/100 ml. during the course of study. 
Interestingly, the splanchnic glucose production fell significantly, 
but this was solely a consequence of a decreased hepatic blood flow, 
inasmuch as the arterio-hepatic venous glucose difference was unchanged. 
In contrast to the significant decrease in insulin noted with propranolol 




PERIPHERAL, SPLANCHNIC GLUCOSE BALANCE AND 
ARTERIAL INSULIN LEVELS DURING SALINE INFUSION 




l± U/ ml 
( N = 4 ) 
TIME (min) 
FIGURE 8 Arterio-femoral venous glucose difference; splanchnic glucose 
production; and arterial insulin levels in five anesthetized dogs in 
the basal postabsorptive state and after a 3 minute infusion of saline. 
Mean values ± S.E. are shown. P values are based on paired t test. 
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Himms-Hagen in her review of the sympathetic regulation of metabolism 
in 1967 (54) pointed out the large gap in knowledge with respect to the 
effects of epinephrine on protein and amino acid metabolism. Up to that 
point in time epinephrine was felt to decrease the concentration of amino 
acids in the blood (16, 55, 56). It was postulated that accelerated 
gluconeogenesis from amino acids would be a logical explanation for this 
observation but no direct evidence was available. In fact, evidence 
in the perfused liver suggested that epinephrine did not alter gluconeo¬ 
genesis (57). However, London and Prenton reporting on the plasma amino 
acid response to insulin in man found a drop in plasma a-amino nitrogen 
after intravenous insulin and suggested that this drop might be related 
to the effect of epinephrine secretion following insulin-induced hypoglycemia 
(58). They postulated that the mechanism might be the promotion of the 
tissue uptake of amino acids by epinephrine and cited the work of Sanders 
and Riggs who showed that epinephrine stimulated the uptake of two 
non-metabolizable amino acids, 1-aminocyclopentanecarboxylic acid and 
a-aminoisobutyric acid (19). However, lacking in all these reports, were 
observations on the effect of epinephrine on individual arterial amino 
acids and their uptake or release by various tissues, particularly the 
liver. 
In examining the current data one needs to evaluate first the baseline 
measurements of the individual arterial amino acids and their relationship 
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to gluconeogenesis in the basal state. In the basal anesthetized state 
measurement of fifteen individual amino acids by column chromatography 
revealed a pattern similar to that previously described in man (23). 
Of the individual amino acids measured alanine not only was present in a 
much greater concentration than the other amino acids but also accounted for 
a majority of the total net splanchnic amino acid consumption, suggesting a 
primary role of alanine in gluconeogenesis. This is in excellent agreement 
with the work of Felig et. al. who demonstrated that the gluconeogenic 
amino acids - alanine, glycine, threonine, and serine - account for 
over 85 per cent of the net splanchnic uptake of amino acids in normal post- 
absorptive subjects with alanine by far representing the largest amino acid 
precursor of new glucose formation (21). In fact , the basal uptake of alanine 
reported in this study agrees quite closely with that described in man (24, 51). 
The current data therefore testifies to the role of alanine in basal post- 
absorptive gluconeogenesis and reconfirms the concept of the glucose alanine-cycle 
described by Felig et. al. (22). Thus, in the present study, alanine has 
been shown to be the predominant arterial amino acid as well as being 
significantly extracted by the liver for gluconeogenesis. 
The results of the epinephrine infusion suggest that in exerting its hyper¬ 
glycemic effect, this hormone not only may influence glycogenolysis but also 
may augment gluconeogenesis. Following initiation of the infusion, an 
immediate rise in both arterial glucose and splanchnic glucose production 
was noted at 10 and 20 minutes concurring with the previous work of 
Bearn et. al. (8) and Porte (12). These investigators demonstrated a 
similar rise in plasma glucose levels and splanchnic glucose production 
in human subjects during a constant infusion of epinephrine at a dose 
T 
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equivalent to that employed in the present study. 
Concurrent with the rapid rise in arterial glucose and splanchnic 
glucose production, the splanchnic uptake of alanine increased by 
37 per cent during the initial 10 to 20 minutes after beginning the 
infusion. In view of previous observations that alanine is the key 
endogenous substrate for gluconeogenesis C22) and its availability 
is the rate limiting step in gluconeogenesis (20) the current data 
suggests that epinephrine stimulates gluconeogenesis as well as 
glycogenolysis. Furthermore, inasmuch as the increase in alanine uptake 
was not due to a rise in arterial concentration of this amino acid, 
the data suggests that the stimulatory effect of epinephrine on 
gluconeogenesis is a consequence of a direct hepatic effect rather 
than a result of an action on peripheral precursor supply. 
However, it was also observed that, although the absolute rate of alanine 
uptake increased in the experimental period as compared with the control 
period, the potential yield of new glucose from alanine as a percentage 
of the total splanchnic glucose production decreased. In other words, 
although more alanine was extracted by the liver during the epinephrine 
infusion, it represented less of the total glucose output as compared 
with control values. This observation suggests that in the postabsorptive 
state, the dog's liver is not depleted of glycogen stores and that 
glycogen breakdown along with glucose formation from precursors such as 
lactate make up the largest share of the observed increase in splanchnic 
glucose output after epinephrine. Support for this conclusion comes from 
the work done on glucose homeostasis during starvation. The data of 
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Felig and co-workers demonstrated similar postabsorptive values for arterial 
alanine levels and splanchnic uptake as in the present study (24, 51). However, 
after a 36 to 48 hour fast these investigators demonstrated a significant, 
almost two-fold increase in splanchnic alanine extraction (20), suggesting 
that postabsorptively the liver does not rely significantly on amino acid 
precursors to maintain splanchnic glucose production. It is not until 
at least 36 to 48 hours later when glycogen stores are presumably depleted 
that gluconeogenesis assumes a more important role in maintaining glucose 
homeostasis. This does not detract from the observation in the present study 
that in the postabsorptive state epinephrine is capable in small amounts of 
causing a significant increase in amino acid uptake, presumably for gluconeo¬ 
genesis. In fact, one might then expect that epinephrine-stimulated 
gluconeogenesis would become a more prominent factor in maintaining splanchnic 
glucose production as glycogen stores were depleted in the early phase of 
starvation. 
It was also observed in the present study that arterial alanine levels 
did not fall despite an increase in splanchnic uptake of this amino acid. 
This fact suggests that there was an increase in the production of 
alanine peripherally. In view of this observation, it is noteworthy 
that epinephrine has been demonstrated to stimulate the release of 
lactate and pyruvate from the periphery (_4, 5, 10). Also, Felig et. al. 
have shown that during exercise peripheral alanine formation increases 
as pyruvate and lactate formation increase with arterial alanine levels 
rising in direct proportion to the increase in arterial pyruvate (24). 
Therefore, it is possible that epinephrine-induced muscle glycogenolysis 
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stimulated alanine release as well as lactate and pyruvate release. And, 
as a consequence, arterial alanine levels did not decline. 
Also significant in the present study was the lack of change in the 
arterial concentration of the individual amino acids, particularly the 
branched-chain amino acids, phenylalanine, and tyrosine after epinephrine 
administration. This fact is noteworthy in view of the suggestion of London and 
Prenton in 1968 that epinephrine released as a result of insulin-induced 
hypoglycemia may produce a lowering of plasma amino acid levels (58). The 
current data shows no evidence that epinephrine has a hypoaminoacidemic effect. 
Therefore, the effect of insulin on amino acid levels must be a direct one. This 
fact has been well demonstrated by Felig et. al. who have shown the direct and 
exquisite sensitivity of the branched-chain amino acids, phenylalanine, and 
tyrosine to alterations in endogenous insulin secretion in normal human subjects 
(52) . 
Lastly, the possibility must be considered that epinephrine might act indirectly 
through the secretion of glucagon, a hormone known to increase gluconeogenesis 
(10). This has been suggested by studies demonstrating that in the in vitro 
perfused liver epinephrine does not increase liver glucose production, whereas 
glucagon does (18) . Further studies employing measurement of immunoassayable 
glucagon will be necessary to clarify this point. 
II. PROPRANOLOL 
The influence of g-receptor blocking agents with regard to glucose 
-m 
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homeostasis must be viewed against the backdrop of the mass of 
information available as to the role of a and 3 receptors in modifying 
glucose, insulin, and free fatty acid concentrations in plasma. Much 
of this work is based on the relative potency of isoproterenol, epinephrine, 
and norepinephrine in stimulating either a or 3 receptors, with isoproterenol 
considered a predominantly 3-receptor stimulator, epinephrine both an 
a and 3 stimulator, and norepinephrine predominantly an a-receptor 
stimulator. It is generally agreed that a-blocking agents block epinephrine- 
induced hyperglycemia in rats (59) and rabbits (60); that 3-blocking 
agents block this hyperglycemia in rats (61) and dogs (62); and, that 
neither agent alone blocks this response in man (63). This evidence 
has led to the conclusion that receptors responsible for epinephrine- 
mediated hyperglycemia are a and 3 in the rat, 3 in the dog, and neither 
a or 3 alone in man (54). With regard to insulin, mediation of its secretion 
now seems predictable on a receptor basis with a-receptors inhibiting insulin 
secretion and with 3-receptors enhancing insulin secretion (12). In terms of 
the receptor schema for lipolysis the rise of free fatty acids induced by 
epinephrine in man can be blocked by 3 but not by a-blocking agents suggesting 
that the 3-receptor mediates lipolysis (64). 
Against this background, the present results indicate that propranolol 
causes a modest but significant decrease in arterial glucose levels. 
At the same time that the arterial glucose level fell, splanchnic glucose 
production failed to decline significantly. Moreover, the failure of splanchnic 
glucose production to fall despite a significant decrease in splanchnic blood 
flow suggests that following propranolol administration each functional liver 
unit actually produced more glucose, perhaps as a consequence of the decrease 
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in insulin levels. This lack of inhibition by propranolol of splanchnic 
glucose production suggests that hepatic glycogenolysis in the dog in the basal 
state is not solely dependent on 3-adrenergic stimulation. This is in agreement 
with the observations made in human subjects by Antonis et. al. that neither 
a or 3-blockade alone abolishes epinephrine-induced hyperglycemia but that 3~ 
blockade inhibits lactate production suggesting that a-receptors are located in 
the liver while 3-receptors are located in muscle (35). 
In contrast to the findings on splanchnic glucose production the arterio- 
femoral venous glucose difference increased by 350 per cent. The true index 
of peripheral glucose utilization is the product of the peripheral blood flow 
and the arterio-femoral venous glucose difference. Although data is lacking 
in the literature on the effect of propranolol on peripheral blood flow in 
the normal dog in the postabsorptive state, it is unlikely that a decrease in 
blood flow could totally account for a three to four-fold increment in the glucose 
concentration gradient across the limb. This is reinforced by the lack of 
marked changes in hemodynamics in the present study as suggested by the fact 
that propranolol did not cause a bradycardia in any of the dogs and had less 
of an effect on splanchnic blood flow than was observed in the saline controls. 
Also, the observed decrease in arterial glucose concentration without a concomi¬ 
tant fall in splanchnic glucose production strongly suggests an increase in 
the peripheral utilization of glucose. The data thus would appear to support 
the conclusion that propranolol lowers blood glucose levels by increasing 
peripheral glucose consumption. 
As to the physiologic mechanism by which propranolol causes an increase 
in the peripheral glucose uptake, it is noteworthy that a 57 per cent 
diminution in circulating insulin levels was observed in the present 
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study. The latter finding is in agreement with the receptor schema 
for insulin as previously described and is in accord with the data of 
Robertson and Porte who demonstrated a similar fall in insulin levels 
in human subjects given an infusion of propranolol (65). In view 
of the hypoinsulinemia, it would appear that propranolol increases glucose 
uptake by increasing the peripheral effectiveness of insulin. This conclu¬ 
sion is in accord with the in vitro work of Abramson and Arky who found that 
propranolol augmented insulin effectiveness on glucose uptake by rat 
hemidiaphrams (31). 
As to the biochemical basis of propranolol's action on glucose uptake, 
Kipnis et. al. have demonstrated that epinephrine inhibits insulin- 
stimulated peripheral glucose uptake by causing the cellular accumulation 
of glucose-6-phosphate (66). The latter, in turn, inhibits hexokinase 
activity (67), presumably making phosphorylation rather than membrane 
transport the rate limiting step in glucose uptake. Thus, any blockade 
by propranolol of the formation of glucose-6-phosphate would prevent 
epinephrine antagonism of insulin-induced glucose uptake (31, 68), 
presumably allowing not only a greater uptake of glucose but also 
a lower rate of insulin secretion. Thus, although data is lacking on 
propranolol's effect on epinephrine-stimulated muscle glycogenolysis, 
this hypothesis along with the data presented point to a fertile field 
of endeavor on the biochemical level. 
The current findings also suggest that there is a significant level 
of endogenous sympathetic tone in the anesthetized dog. Thus, the 
peripheral contra-insulin effects of this basal sympathetic tone may be 
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obliterated with propranolol. In addition, propranolol also serves to 
eliminate the 3-adrenergic stimulatory component of basal insulin 
secretion. As a consequence, serum insulin levels decline. 
Finally, the clinical relevance of these findings in the dog to man 
lies in the increasing uses of propranolol, and thus, the caution that 
must be observed so as not to precipitate attacks of hypoglycemia. 
Also, if indeed, a major effect in man of propranolol is to increase the 
peripheral sensitivity of muscle and adipose tissue to insulin, then 
quite possibly the physician will have another tool in his armentarium 
in attempting to treat the brittle diabetic. This idea is supported 
by the recent observations of Baker et. al. that emotionally stressed, 
ketotic-prone diabetic children improve considerably in terms of 
morbidity, i.e. ketoacidosis, while maintained on prophylactic 3-blocking 
agents such as propranolol (69). This suggests the need for further 
investigation and correlation of the physiologic and biochemical mechanisms 





Seven dogs were given a constant infusion of epinephrine at a rate of 
0.1 yg/kg/min. over a 60 minute period and arterial glucose levels, 
splanchnic glucose production, arterial levels of individual amino acids, 
and splanchnic uptake of the gluconeogenic amino acids were measured. 
Arterial glucose and splanchnic glucose production increased within 10 to 
20 minutes after the start of the infusion, gradually returning to baseline 
in the recovery period. The splanchnic uptake of alanine increased signifi¬ 
cantly. However, the arterial levels of the individual amino acids, particu¬ 
larly, alanine, did not change. It is concluded that in anesthetized dogs 
in the postabsorptive state that epinephrine exerts its hyperglycemic action 
not only by glycogenolysis but also by stimulating gluconeogenesis via a 
direct hepatic action. 
II. PROPRANOLOL 
Infusion of propranolol in nine dogs at a dose of 150 yg/kg over 3 minutes 
resulted in a decrease in arterial glucose and arterial insulin concentrations. 
Despite the fall in insulin, the arterio-femoral venous glucose difference 
increased more than three-fold while splanchnic glucose production was 
not consistently changed. In the five additional dogs given a saline 
infusion the peripheral gradient for glucose and the arterial insulin levels 
remained stable during a comparable four hour period of study. It is 
concluded that in anesthetized dogs in the postabsorptive state propranolol 
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reduces arterial glucose levels by increasing the peripheral utilization 
of glucose rather than by affecting splanchnic glucose production. This 
increase in peripheral glucose utilization in the face of a declining 
arterial insulin level suggests an increased muscle and adipose tissue 
sensitivity to available insulin. Furthermore, this data suggests that 
there is significant endogenous sympathetic tone in the anesthetized dog 
in the basal state and that propranolol may obliterate the contra-insulin 
effects of this tone. Thus, the influence of g-adrenergic activity on 
glucose hemeostasis is dependent in part on changes related to the peripheral 
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